WCM
EBS icon

Wedge Capital Management’s Emergent Biosolutions EBS Stock Holding History

Wedge Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-14,432
Closed -$729K – 610
2019
Q1 		$729K Buy
+14,432
New +$851K 0.01% 410
2016
Q4 		– Sell
-16,476
Closed -$519K – 573
2016
Q3 		$519K Buy
+16,476
New +$479K 0.01% 430

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Wedge Capital Management's EBS Position: Q2 2019 in Review

Wedge Capital Management sold out of Emergent Biosolutions (EBS) in Q2 2019, closing a stake of 14,432 shares — an estimated $729K sold.

Wedge Capital Management first reported a position in EBS in Q3 2016 and held it in 2 quarters. The position peaked at $729K in Q1 2019. 233 funds tracked by Wall St. Rank hold EBS as of Q2 2019.

  • Wedge Capital Management reported no remaining Emergent Biosolutions position as of Q2 2019 after selling out during the quarter.
  • Wedge Capital Management sold 14,432 Emergent Biosolutions shares in Q2 2019, an estimated $729K.
  • Wedge Capital Management first reported a position in Emergent Biosolutions in Q3 2016 and held it in 2 quarters.
  • Wedge Capital Management's Emergent Biosolutions position peaked at $729K in Q1 2019.
  • 233 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2019.

Based on Wedge Capital Management's 13F filing for Q2 2019, filed 1 Aug 2019.